Clinical Strategies for the Primary Health Care Professional to Minimize Prescription Opioid Abuse

References

• . US Department of Health and Human Services. SAMHSA. Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: National Findings. Volume 1. Summary of National Findings. http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9results.htm. Accessed April 1, 2012
   Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, ; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24(2):141–144
   PubMedGoogle Scholar
• . Governale L. Outpatient presciption opioid utilization in the US, years 2000–2009. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementADvisoryCommittee/UCM220950.pdf. Accessed June 27, 2011
   Google Scholar
• . Caudill–Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514–519
   PubMed Web of Science ®Google Scholar
• . Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225–235
   PubMed Web of Science ®Google Scholar
• . American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28–29
   PubMedGoogle Scholar
• . Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24(2):141–144
   PubMedGoogle Scholar
• . US Government Accountability Office. Prescription pain reliever abuse: agencies have begun coordinating education efforts, but need to assess effectiveness. December 2011. http://www.gao.gov/products/GAO-12-115. Accessed March 19, 2012. Publication No. GAO-12-115
   Google Scholar
• . Portenoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in Pain Research and Management. Vol 1. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle, WA: IASP Publications; 1994:247–287
   Google Scholar
• . Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–582
   PubMed Web of Science ®Google Scholar
• . Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9(8):1098–1106
   PubMed Web of Science ®Google Scholar
• . Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11(4):203–217
   PubMed Web of Science ®Google Scholar
• . Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671–681
   PubMed Web of Science ®Google Scholar
• . Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372
   PubMed Web of Science ®Google Scholar
• . Reid MC, Engles–Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173–179
   PubMed Web of Science ®Google Scholar
• . Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007;3(2):89–100
   PubMedGoogle Scholar
• . Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307–315
   PubMed Web of Science ®Google Scholar
• . Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics. 2006;118(6):2472–2480
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562–575
   PubMed Web of Science ®Google Scholar
• . Nwokeji ED, Rascati KL, Brown CM, Eisenberg A. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther. 2007;29( suppl):2589–2602
   PubMed Web of Science ®Google Scholar
• . Potter M, Schafer S, Gonzalez–Mendez E, . Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract. 2001;50(2):145–151
   PubMed Web of Science ®Google Scholar
• . Morley–Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain. Pain Res Manag. 2003;8(4):189–194
   PubMedGoogle Scholar
• . Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107–112
   PubMed Web of Science ®Google Scholar
• . Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10( suppl 2):S79–S88
   PubMed Web of Science ®Google Scholar
• . Smith H, Fine P, Passik S. Opioid Risk Management: Tools and Tips. Oxford University Press, Inc.; 2009
   Google Scholar
• . Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507–513
   PubMed Web of Science ®Google Scholar
• . Fanciullo GJ, Washington T. Best practices to reduce the risk of drug-drug interactions: opportunities for managed care. Am J Manage Care. 2011;17( suppl 11):S299–S304
   PubMedGoogle Scholar
• . Pergolizzi JV. Quantifying the impact of drug-drug interactions associated with opioids. Am J Manage Care. 2011;17( suppl 11):S288–S292
   PubMedGoogle Scholar
• . Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66–73
   PubMed Web of Science ®Google Scholar
• . Butler SF, Budman SH, Fernandez KC, . Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1–2):144–156
   PubMed Web of Science ®Google Scholar
• . McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011; 123(2):119–130
   PubMed Web of Science ®Google Scholar
• . Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70–83
   PubMed Web of Science ®Google Scholar
• . Meltzer EC, Rybin D, Saitz R, . Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011;152(2):397–402
   PubMed Web of Science ®Google Scholar
• . Reisfeld GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37(4):301–314
   PubMedGoogle Scholar
• . Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260–267
   PubMed Web of Science ®Google Scholar
• . McCarberg BH. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrad Med. 2011;123(6):124–131
   PubMed Web of Science ®Google Scholar
• . Donovan MI, Evers K, Jacobs P, Mandleblatt S. When there is no benchmark: designing a primary care-based chronic pain management program from the scientific basis up. J Pain Symptom Manage. 1999;18(1):38–48
   PubMedGoogle Scholar
• . Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999;18(1):27–37
   PubMed Web of Science ®Google Scholar
• . Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A flve year experience. J Gen Intern Med. 2007;22(4):485–490
   PubMed Web of Science ®Google Scholar
• . Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8(7):573–584
   PubMed Web of Science ®Google Scholar
• . Alliance of States with Prescription Monitoring Programs. About the Alliance. http://www.pmpalliance.org/content/about-alliance. Accessed September 12, 2011
   Google Scholar
• . Alliance of States with Prescription Monitoring Programs. Guidelines. Prescription Monitoring Program Goals. http://www.pmpalliance.org/pdfs/resourcespdfs/goalsprescripmonitor.pdf. Accessed August 12, 2011
   Google Scholar
• . Alliance of States with Prescription Monitoring Programs. Resources. http://www.pmpalliance.org/pdf/pmp_memb_list_2011_b.pdf. Accessed September 12, 2011
   Google Scholar
• . Bohnert AS, Valenstein M, Bair MJ, . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–1321
   PubMed Web of Science ®Google Scholar
• . Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid thearpy: a case report and review of the literature. J Opioid Manag. 2011;7(2):145–154
   PubMedGoogle Scholar
• . Angst MS, Clark JK. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–587
   PubMed Web of Science ®Google Scholar
• . Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. 1996;21(11):1375–1386
   PubMed Web of Science ®Google Scholar
• . Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750–1756
   PubMed Web of Science ®Google Scholar
• . Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004; 23(4):1–9
   PubMed Web of Science ®Google Scholar
• . Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618–631
   PubMed Web of Science ®Google Scholar
• . Shram MJ, Sathyan G, Khanna S, . Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25–33
   PubMed Web of Science ®Google Scholar
• . Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13
   PubMedGoogle Scholar
• . Exalgo (hydromorphone HCl) extended-release tablets [package insert]. Hazelwood, MO: Mallinckrodt Inc.; 2010
   Google Scholar
• . OxyContin (oxycodone hydrochloride controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010
   Google Scholar
• . Avinza (morphine sulfate extended-release capsules) [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2008
   Google Scholar
• . Opana ER (oxymorphone hydrochloride) extended-release tablets [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2008
   Google Scholar
• . Kadian (morphine sulfate extended-release) capsules [package insert]. Morristown, NJ: Actavis Elizabeth LLC; 2010
   Google Scholar
• . MS Contin (morphine sulfate controlled-release) tablets [package insert]. Stamford, CT: Purdue Pharma L.P.; 2009
   Google Scholar
• . Oramorph SR (morphine sulfate) sustained release tablets [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc.; 2006
   Google Scholar
• . Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11–18
   PubMedGoogle Scholar
• . Embeda (morphine sulfate and naltrexone hydrochloride) [package insert]. Bristol, TN: King Pharmaceuticals; 2009
   Google Scholar
• . US Food and Drug Administration. OxyContin—Questions and Answers. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/ucm207196.htm. Accessed September 12, 2011
   Google Scholar
• . Pande P, Hines J, Brogan A. Tamper-resistant properties of once-daily hydromorphone ER (OROS Hydromorphone ER). Poster presented at the American Pain Society 30th Annual Scientific Meeting, May 19–21, 2011, Austin, TX. Poster presentation: 331
   Google Scholar
• . Cassidy TA, Coplan P, Black RA, Chilcoat H, Budman SH, Butler SF. Initial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® (oxycodone HCL controlled-release) Tablets in a sentinel surveillance system of patients in substance use treatment. Presented at PAINWeek 2011, September 7–10, 2011; Las Vegas, NV
   Google Scholar
• . Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657–1675
   PubMed Web of Science ®Google Scholar
• . Offce of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. http://www.whitehousedrugpolicy.gov/publications/pdf/rx_abuse_plan.pdf. Accessed July 25, 2011
   Google Scholar
• . US Food and Drug Administration. Post-Approval REMS Notification Letter. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf. Accessed July 29, 2011
   Google Scholar
• . US Food and Drug Administration. Questions and answers: FDA requires a risk evaluation and mitigation strategy (REMS) for long-acting and extended-release opioids. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251752.htm. Accessed July 29, 2011
   Google Scholar
• . US Food and Drug Administration. Medication Disposal: Questions and Answers. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186188.htm. Accessed August 12, 2011
   Google Scholar